Prosecution Insights
Last updated: April 19, 2026
Application No. 18/296,680

Ribonucleic Acid (RNA) Detection Device

Non-Final OA §112
Filed
Apr 06, 2023
Examiner
HOBBS, MICHAEL L
Art Unit
1799
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Keycore Technology Corp.
OA Round
1 (Non-Final)
69%
Grant Probability
Favorable
1-2
OA Rounds
3y 4m
To Grant
97%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
785 granted / 1144 resolved
+3.6% vs TC avg
Strong +29% interview lift
Without
With
+28.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
31 currently pending
Career history
1175
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
41.8%
+1.8% vs TC avg
§102
26.2%
-13.8% vs TC avg
§112
19.1%
-20.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1144 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 04/06/2023 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3 and 10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 recites the limitation "the dielectric constant" in line 1. There is insufficient antecedent basis for this limitation in the claim. For claim 10, it is unclear if this is only one of the conductive components or if this applies to all of the multiple conductive components of claim 1. It is recommended to amend this to either be the multiple conductive components or at least one of the multiple conductive components in order to clarify this claim. Clarification and appropriate corrective action is required. Allowable Subject Matter Claims 1, 2, 4-9 and 11 are allowed. The following is an examiner’s statement of reasons for allowance: For claim 1, the prior art taken either singly or in combination fails to teach or reasonably suggest the following limitation when taken in context of the claim as a whole a ribonucleic acid detection device that includes the following limitations: a case, having a detection hole on the surface thereof for receiving a specimen liquid; a substrate, located inside the case and including: a first layer board, which has an RNA detection panel and a metal mask cover covering the RNA detection panel, in which the RNA detection panel is an active thin film transistor panel, and the metal mask cover has a concave opening whose location corresponds to the position of the detection hole and the surface of the RNA detection panel such that the specimen liquid entered by way of the detection hole can contact the surface of the RNA detection panel through the concave opening, and, in addition, around the RNA detection panel, a metal conductive trigger strip is set up on the first layer board of the substrate, and the metal mask cover presses on the metal conductive trigger strip, and the surface of the RNA detection panel is combined with a protective layer; a second layer board, electrically connected to the first layer board and being a sensor circuit board having a sensor chip, in which the RNA detection panel is electrically connected to the first layer board by means of multiple conductive components and the sensor circuit board is used to transfer an activation signal to the metal conductive trigger strip and, after amplifying the activation signal through the metal mask cover, enables the specimen liquid on the surface of the RNA detection panel to generate a change of electrical charge, such that the RNA detection panel transfers a detection signal to the detection circuit board in accordance with the change of electrical charge, and the sensor chip generates a specimen signal determination value based on the detection signal; and a processing circuit board, electrically connected to the detection circuit board and used to receive the specimen signal determination value generated by the sensor chip, in which the processing circuit board includes a control and determination unit which is used to generate a determination result based on the specimen signal determination value. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Claims 3 and 10 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. The prior art does not teach or fairly suggest the limitations of claims 3 and 10. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Chiang et al. (US 2021/0354127 A1) discloses a system for detecting COVID-19 or other RNA viruses. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL L HOBBS whose telephone number is (571)270-3724. The examiner can normally be reached Variable, but generally 8AM-5PM M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Marcheschi can be reached at 571-272-1374. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL L HOBBS/Primary Examiner, Art Unit 1799
Read full office action

Prosecution Timeline

Apr 06, 2023
Application Filed
Oct 24, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600932
BIOPROCESSING PERFUSION SYSTEM HAVING A PLURALITY OF FILTERS AND METHOD OF OPERATING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12595449
INTEGRATED SYSTEM FOR 3D TISSUE CULTURE
2y 5m to grant Granted Apr 07, 2026
Patent 12590282
CELL CULTURE APPARATUS
2y 5m to grant Granted Mar 31, 2026
Patent 12590279
SUBSTRATE OF CELL CULTURE CONTAINER, AND CELL CULTURE CONTAINER
2y 5m to grant Granted Mar 31, 2026
Patent 12584089
SENSING VESSELS FOR CELL CULTURES
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
69%
Grant Probability
97%
With Interview (+28.8%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 1144 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month